Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum A Case Series and Literature Review

Department of Dermatology, University of California at San Francisco, CA, USA.
Archives of dermatology (Impact Factor: 4.31). 11/2010; 146(11):1265-70. DOI: 10.1001/archdermatol.2010.328
Source: PubMed

ABSTRACT Hidradenitis suppurativa (HS) and pyoderma gangrenosum (PG) are both rare inflammatory skin conditions that are associated with systemic inflammatory diseases. We performed a retrospective medical chart review of patients with an overlap of HS and PG.
We identified 11 cases of PG lesions presenting in patients with HS. Ten of the patients were women, and 9 were obese. All the patients developed HS lesions first, a median of 2.5 years (range, 0-15 years) preceding the appearance of PG lesions. All patients required multiple therapeutic agents because their diseases were often poorly responsive to standard therapies. Two patients received tumor necrosis factor inhibitors; 1 responded to treatment. One patient was treated with anakinra (interleukin-1 receptor antagonist) and had a 75% improvement of her lesions.
We have identified a group of patients who have an overlap of PG and HS. Pyoderma gangrenosum can appear at any point after the development of HS and often has a severe, refractory course. We propose that PG and HS may represent variant manifestations of cytokine dysregulation by the innate immune system with common etiology. New therapeutic agents are eagerly sought, and further investigation with regard to interleukin 1 blockade is warranted.

Download full-text


Available from: Richard joseph Antaya, Dec 09, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hidradenitis suppurativa, or Verneuil's disease, is common, especially in women, but it is often undiagnosed. Clinical manifestations include painful nodules, abscesses, sinus tracts, and rope-like hypertrophic scars in the apocrine gland-bearing areas (axillae, groins, genitals, perianal area). It is a chronic and severe disease. Smoking and obesity are risk factors, but its cause is unknown: it is a disease of the follicular apparatus, neither infectious nor hormonal. Severe dramatic forms are rare. Quality of life is severely affected, even in the mild forms. Treatment is both medical and surgical: wide-spectrum antibiotics and excisions tailored to the extent of involvement. Anti-TNF-α agents are moderately effective; their risk–benefit ratio is still in question. Laser treatment is under study. Spondylarthropathies in the setting of Crohn's disease, as an association, or isolated can also be a diagnostic feature of Verneuil's disease, and can occur during disease flares.
    Revue du Rhumatisme Monographies 06/2011; 78(3):152-157. DOI:10.1016/j.monrhu.2011.03.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease. Since current treatments are unsatisfactory for many patients, there is a high need for effective drugs for this debilitating disease. Recent pathogenic insights suggest inflammasome activation and IL-1β production are important in HS. Colchicine is efficacious in the IL-1β- and inflammasome-mediated diseases gout, familial Mediterranean fever and Behçet's disease, and therefore a potentially effective drug in HS. To investigate the efficacy of colchicine in HS. Methods: In an open prospective pilot study, 8 HS patients were treated with the accepted gout maintenance regimen of 0.5 mg colchicine b.i.d. orally up to 4 months. Efficacy was assessed by a physician global assessment. Colchicine treatment did not result in a clinically relevant improvement of disease severity. Three patients experienced nausea and diarrhea as known side effects. Colchicine in the used dose regimen does not ameliorate HS severity.
    Dermatology 11/2011; 223(2):169-73. DOI:10.1159/000332846 · 1.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful, necrotic ulceration. It typically affects patients in the third to sixth decades of life, with almost equal incidence in men and women. PG occurs most frequently on the lower extremities. Five clinical variants are currently recognized: classic, bullous, pustular, vegetative, and peristomal types. Half of PG cases are seen in association with systemic disease. Mimickers include infection, vascular insufficiency ulcers, systemic vasculitides, autoimmune disease, cancer, and exogenous tissue injury, among others. PG is often a diagnosis of exclusion, as there are no specific laboratory or histopathologic findings to confirm the diagnosis. PG thus presents many clinical challenges: it is difficult to diagnose, is frequently misdiagnosed, and often requires a work-up for underlying systemic disease. Successful management of PG typically requires multiple modalities to reduce inflammation and optimize wound healing, in addition to treatment of any underlying diseases. Prednisone and cyclosporine have been mainstays of systemic treatment for PG, although increasing evidence supports the use of biologic therapies, such as tumor necrosis factor-α inhibitors, for refractory cases of PG. Here, we review the clinical presentation and pathophysiology of PG, as well as its associated conditions, diagnostic work-up, and management.
    American Journal of Clinical Dermatology 02/2012; 13(3):191-211. DOI:10.2165/11595240-000000000-00000 · 2.52 Impact Factor
Show more